Bitter gourd (Momordica charantia): A review of its efficacy and safety for glucose homeostasis

Nutritional Sciences Journal

Volumn 35, Issue 3, 2010, Pages 115-126

  Tsai, Chung Huang ^a,b   Chen, Emily Chin Fun ^b   Tsay, Hsin Sheng ^b   Huang, Ching Jang ^c,d  

^a CHENG CHING GENERAL HOSPITAL   (Taiwan)

^b CHAOYANG UNIVERSITY OF TECHNOLOGY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d HUNGKUANG UNIVERSITY   (Taiwan)

Author keywords

Blood glucose; Cucurbltane type triterpenoid; Diabetes; Momordica charantia; Peroxisome proliferator activated receptor

Indexed keywords

ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; MOMORDICA CHARANTIA EXTRACT;

ABDOMINAL PAIN; ARTICLE; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FAVISM; GASTROINTESTINAL DISEASE; GLUCOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HYPOGLYCEMIC COMA; INFERTILITY; INSULIN RELEASE; INSULIN RESISTANCE; MOMORDICA CHARANTIA; NONHUMAN; PANCREAS ISLET BETA CELL;

ANIMALIA; MOMORDICA CHARANTIA; MUS; RODENTIA;

EID: 84863229988     PISSN: 10116958     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Dans AM, Villarruz MV, Jimeno CA, Javelosa MA, Chua J, Bautista R, Velez GG. The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. J Clin Epidemiol. 2007;60:554-9. (Pubitemid 46686996)
2. Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm. 2003;60:356-9. (Pubitemid 36749034)
3. Nivitabishekam SN, Asad M, Prasad VS. Pharmacodynamic Interaction Of 15)Momordica charantia with rosiglitazone in rats. Chem Biol Interact. 2009;177:247-53.
4. Chao CY, Huang Cj. In vitro activation of peroxisome proliferator activated-receptor or by some extracts from food materials. J Food Drug Anal. 2008;16:62-9.
5. Chou YM, Chao CY. Wild bitter gourd extracts activate the transcription factor, PPARγ, and inhibit LPS-induced inflammatory responses in RAW264.7 cells. Nutr Sci J. 2008;33:108-15.
6. Sasa M, Inoue I, Shinoda Y, Takahashi S, Seo M, Komoda T, Awada T, Katayama S. Activating effect of momordin, extract of bitter melon (Momordica charantia L.), on the promoter of human PPARδ. J Atheroscler Thromb. 2009;16:888-92.
7. Shih CC, LIn CH, Lin WL. Effects of Momordica charantia on Insulin resistance and visceral obesity in mice on high-fat diet. Diabetes Res Clin Pract. 2008;81:134-43.
8. Huang HL, Hong YW, Wong YH, Chen YN, Chyuan JH, Huang CJ, Chao PM. Bitter melon (Momordica charantia L.) inhibits adipocyte hypertrophy and down regulates lipogenic gene expression in adipose tissue of diet-induced obese rats. Br J Nutr. 2008;99:230-9.
9. Yasuda M, Iwamoto M, Okabe H, Yamauchi T. Structures of momordicines I, II, and III. The bitter principles in the leaves and vines of Momordica charantia L. Chem Pharm Bull. 1984;32:2044-7.
10. Handa GJ, Singh ML, Sharma A, Kaul N, Zafar R. Hypoglycemic principle of Momordica charantia seeds. Indian J Nat Prod. 1990;6:16-9.
11. Khanna P, Jain SC, Panagariya A, Dixit VP. Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod. 1981;44:648-55. (Pubitemid 12152470)
12. Matsuur H, Asakawa C, Kurimoto M, Mizutani J. αglucosidase inhibitor from the seeds of balsam pear (Momordica charantia) and the fruit bodies of Grifola frondosa. Biosci Biotechnol Biochem. 2002;66:1576-8. (Pubitemid 39246868)
13. Tan MJ, Ye JM, Turner N, Hohnen-Behrens C, Ke CQ, Tang CP, Chen T, Weiss HC, Gesing ER, Rowland A, James DE, Ye Y. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol. 2008;15:263-73. (Pubitemid 351381992)
14. Harinantenaina L, Tanaka M, Takaoka S, Oda M, Mogami O, Uchida M, Asakawa Y. Momordica charantia constituents and antidiabetic screening of the isolated major compounds. Chem Pharm Bull (Tokyo). 2006;54:1017-21.
15. Cheng HL, Huang HK, Chang CI, Tsai CP, Chou CH. A cell-based screening identifies compounds from the stem of Momordica charantia that overcome insulin resistance and activate AMP-activated protein kinase. J Agric Food Chem. 2008;56:6835-43.
16. Tran Minh N, Young-In K, Hae-Dong J, Young Ho K. α-Glucosidase inhibition properties of cucurbitane-type triterpene glycosides from the fruits of Momordica charantia. Chem Pharm Bull. 2010;58:720-4.
17. Ma J, Whittaker P, Keller AC, Mazzola EP, Pawar RS, White KD, Callahan JH, Kennelly EJ, Krynitsky AJ, Rader JI. Cucurbitane-type triterpenoids from Momordica charantia. Planta Med. 2010. (Epub ahead of print)
18. Uebanso T, Arai H, Taketani Y, Fukaya M, Yamamoto H, Mizuno A, Uryu K, Hada T, Takeda E. Extracts of Momordica charantia suppress postprandial hyperglycemia in rats. J Nutr Sci Vitaminol (Tokyo). 2007;53:482-8. (Pubitemid 351154868)
19. Oishi Y, Sakamoto T, Udagawa H, Taniguchi H, Kobayashi-Hattori K, Ozawa Y, Takita T. Inhibition of increases in blood glucose and serum neutral fat by Momordica charantia saponin fraction. Biosci Biotechnol Biochem. 2007;71:735-40. (Pubitemid 46481449)
20. Meir P, Yaniv Z. An in vitro study on the effect of Momordica charantia on glucose uptake and glucose metabolism in rats. Planta Med. 1985;51:12-6. (Pubitemid 15146405)
21. Mahomoodally MF, Gurib-Fakim A, Subratty AH. Effect of exogenous ATP on Momordica charantia Linn. (Cucurbitaceae) induced inhibition of D-glucose, L-tyrosine and fluid transport across rat everted Intestinal sacs in vitro. J Ethnopharmacol. 2007;110:257-63. (Pubitemid 46283659)
22. Xiang L, Huang X, Chen L, Rao P, Ke L. The reparative effects of Momordica charantia Linn. extract on HIT-T15 pancreatic beta-cells. Asia Pac J Clin Nutr. 2007;16:249-52. (Pubitemid 46524609)
23. Yibchok-Anun S, Adisakwattana S, Yao CY, Sangvanich P, Roengsumran S, Hsu WH. Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities. Biol Pharm Bull. 2006;29:1126-31. (Pubitemid 43845470)
24. Rotshteyn Y, Zito SW. Application of modified in vitro screening procedure for identifying herbals possessing sulfonylurea-like activity. J Ethnopharmacol. 2004;93:337-44. (Pubitemid 38962426)
25. Shibib BA, Khan LA, Rahman R. Hypoglycaemic activity of Coccinia indica and Momordica charantia in diabetic rats: depression of the hepatic gluconeogenic enzymes glucose-6-phosphatase and fructose-1,6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase. Biochem J. 1993; 292 (Pt 1) :267-70. (Pubitemid 23158992)
26. Roffey BW, Atwal AS, Johns T, Kubow S. Water extracts from Momordica charantia Increase glucose uptake and adiponectin secretion in 3T3-L1 adipose cells. J Ethnopharmacol. 2007;112:77-84. (Pubitemid 46702417)
27. Nerurkar PV, Lee YK, Motosue M, Adeli K, Nerurkar VR. Momordica charantia (bitter melon) reduces plasma apollpoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions. Br J Nutr. 2008;100:751-9.
28. Sridhar MG, Vinayagamoorthi R, Arul Suyambunathan V, Bobby Z, Selvaraj N. Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats. Br J Nutr. 2008;99:806-12. (Pubitemid 351351634)
29. Miura T, Itoh C, Iwamoto N, Kato M, Kawai M, Park SR, Suzuki I. Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J Nutr Sci Vitaminol (Tokyo) . 2001;47:340-4. (Pubitemid 33139560)
30. Chen Q, Chan LL, LI ET. Bitter melon (Momordica charantia) reduces adiposity, lowers serum Insulin and normalizes glucose tolerance in rats fed a high fat diet. J Nutr. 2003;133:1088-93. (Pubitemid 36407130)
31. Chuang CY, Hsu C, Chao CY, Wein YS, Kuo YH, Huang Cj. Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARα in bitter gourd. J Biomed Sci. 2006;13:763-72. (Pubitemid 44900649)
32. Kumar R, Balaji S, Sripriya R, Nithya N, Uma TS, Sehgal PK. In vitro evaluation of antioxidants of fruit extract of Momordica charantia L. on fibroblasts and keratinocytes. J Agric Food Chem. 2010;58:1518-22.
33. Horax R, Hettiarachchy N, Chen P. Extraction, quantification, and antioxidant activities of phenolics from pericarp and seeds of bitter melons (Momordica charantia) harvested at three maturity stages (immature, mature, and ripe). J Agric Food Chem. 2010;58:4428-33.
34. Lii CK, Chen HW, Yun WT, Liu KL. Suppressive effects of wild bitter gourd (Momordica charantia Linn. var. abbreviata ser.) fruit extracts on inflammatory responses in RAW264.7 macrophages. J Ethnopharmacol. 2009;122:227-33.
35. Chaturvedi P, George S. Momordica charantia maintains normal glucose levels and lipid profiles and prevents oxidative stress in diabetic rats subjected to chronic sucrose load. J Med Food. 2010;13:520-7.
36. Jayasoorlya AP, Sakono M, Yukizaki C, Kawano M, Yamamoto K, Fukuda N. Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets. J Ethnopharmacol. 2000;72:331-6.
37. Popovich DG, LI L, Zhang W. Bitter melon (Momordica charantia) triterpenoid extract reduces preadipocyte viability, lipid accumulation and adiponectin expression in 3T3-L1 cells. Food Chem Toxicol. 2010;48:1619-26.
38. Ooi CP, Yassin Z, Hamid TA. Momordica charantia for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;2:1-33.
39. Inayat ur R, Malik SA, Bashir M, Khan R, Iqbal M. Serum sialic acid changes in non-insulin-dependant diabetes mellitus (NIDDM) patients following bitter melon (Momordica charantia) and rosiglitazone (Avandia) treatment. Phytomedicine. 2009;16:401-5.
40. Leatherdale BA, Panesar RK, Singh G, Atkins TW, Bailey CJ, Bignell AH. Improvement in glucose tolerance due to Momordica charantia (karela). Br Med J (Clin Res Ed). 1981;282:1823-4. (Pubitemid 11047735)
41. Welihinda J, Karunanayake EH, Sheriff MH, Jayasinghe KS. Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J Ethnopharmacol. 1986;17:277-82. (Pubitemid 17209188)
42. Grover J, Gupta S. Hypoglycemic activity of seeds of Momordica charantia. Eur J Pharmacol. 1990;183:1026-7. (Pubitemid 20258414)
43. Srivastava Y. Antidiabetic and adaptogenic properties of Momordica charantia extract: an experimental and clinical evaluation. Phytother Res. 1993;7:785-9.
44. Ahmad N, Hassan MR, Halder H, Bennoor KS. Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients. Bangladesh Med Res Counc Bull. 1999;25:11-3.
45. Rosales R, Fernando R. An inquiry to the hypoglycemic action of Momordica charantia among type 2 diabetes patients. Philipp J Intern Med. 2001;7:213-6.
46. John AJ, Cherian R, Subhash HS, Cherian AM. Evaluation of the efficacy of bitter gourd (Momordica charantia) as an oral hypoglycemic agent - a randomized controlled clinical trial. Indian J Physiol Pharmacol. 2003;47:363-5. (Pubitemid 36876594)
47. Baldwa V, Bhandra C, Pangaria A, Goyal R. Clinical trials in patients with diabetes mellitus of an insulin-like compound obtained from plant source. Upsala J Med Sci. 1977;82:39-41. (Pubitemid 8098430)
48. Kasbia GS, Arnason JT, Imbeault P. No effect of acute, single dose oral administration of Momordica charantia Linn., on glycemia, energy expenditure and appetite: a pilot study in non-diabetic overweight men. J Ethnopharmacol. 2009;126:127-33.
49. Tennekoon KH, Jeevathayaparan S, Angunawala P, Karunanayake EH, Jayasinghe KS. Effect of Momordica charantia on key hepatic enzymes. J Ethnopharmacol. 1994;44:93-7.